A detailed history of Vanguard Group Inc transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 10,167,614 shares of VKTX stock, worth $524 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
10,167,614
Previous 10,097,337 0.7%
Holding current value
$524 Million
Previous $535 Million 20.26%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$49.84 - $70.47 $3.5 Million - $4.95 Million
70,277 Added 0.7%
10,167,614 $644 Million
Q2 2024

Aug 13, 2024

BUY
$47.39 - $80.2 $110 Million - $185 Million
2,311,613 Added 29.69%
10,097,337 $535 Million
Q1 2024

May 10, 2024

BUY
$17.4 - $94.5 $41.8 Million - $227 Million
2,403,820 Added 44.66%
7,785,724 $638 Million
Q4 2023

Feb 14, 2024

BUY
$9.24 - $19.64 $901,380 - $1.92 Million
97,552 Added 1.85%
5,381,904 $100 Million
Q3 2023

Nov 14, 2023

BUY
$10.92 - $16.0 $1.88 Million - $2.75 Million
171,995 Added 3.36%
5,284,352 $58.5 Million
Q2 2023

Aug 14, 2023

BUY
$14.84 - $24.79 $15.6 Million - $26.1 Million
1,053,718 Added 25.96%
5,112,357 $82.9 Million
Q1 2023

May 15, 2023

BUY
$8.08 - $17.33 $5.92 Million - $12.7 Million
732,968 Added 22.04%
4,058,639 $67.6 Million
Q4 2022

Feb 10, 2023

SELL
$2.72 - $9.4 $14,736 - $50,929
-5,418 Reduced 0.16%
3,325,671 $31.3 Million
Q2 2022

Aug 12, 2022

SELL
$2.11 - $3.15 $737,299 - $1.1 Million
-349,431 Reduced 9.49%
3,331,089 $9.63 Million
Q1 2022

May 13, 2022

BUY
$3.0 - $4.88 $889,059 - $1.45 Million
296,353 Added 8.76%
3,680,520 $11 Million
Q4 2021

Feb 14, 2022

BUY
$4.6 - $6.72 $88,389 - $129,124
19,215 Added 0.57%
3,384,167 $15.6 Million
Q3 2021

Nov 12, 2021

BUY
$5.58 - $7.04 $469,512 - $592,359
84,142 Added 2.56%
3,364,952 $21.1 Million
Q2 2021

Aug 13, 2021

BUY
$5.19 - $6.73 $17 Million - $22.1 Million
3,280,810 New
3,280,810 $19.7 Million

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $3.95B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.